Additional research on biomarkers in "Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) "
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2014 New trial record